Cargando…
mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability
A drawback of the current mRNA-lipid nanoparticle (LNP) COVID-19 vaccines is that they have to be stored at (ultra)low temperatures. Understanding the root cause of the instability of these vaccines may help to rationally improve mRNA-LNP product stability and thereby ease the temperature conditions...
Autores principales: | Schoenmaker, Linde, Witzigmann, Dominik, Kulkarni, Jayesh A., Verbeke, Rein, Kersten, Gideon, Jiskoot, Wim, Crommelin, Daan J.A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032477/ https://www.ncbi.nlm.nih.gov/pubmed/33839230 http://dx.doi.org/10.1016/j.ijpharm.2021.120586 |
Ejemplares similares
-
Addressing the Cold Reality of mRNA Vaccine Stability
por: Crommelin, Daan J.A., et al.
Publicado: (2021) -
The Science is There: Key Considerations for Stabilizing Viral Vector-Based Covid-19 Vaccines
por: Crommelin, Daan J.A., et al.
Publicado: (2021) -
The role of lipid components in lipid nanoparticles for vaccines and gene therapy
por: Hald Albertsen, Camilla, et al.
Publicado: (2022) -
Lipid nanoparticle technology for therapeutic gene regulation in the liver
por: Witzigmann, Dominik, et al.
Publicado: (2020) -
The Storage and In-Use Stability of mRNA Vaccines and Therapeutics: Not A Cold Case
por: Oude Blenke, Erik, et al.
Publicado: (2023)